Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M07D1 + pembrolizumab in HER2-overexpressing non-squamous NSCLC
CTR20254699Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of BL-M07D1, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Biokin Pharmaceutical. Started Feb 2026; status: active.
02
Drugs
BL-M07D1pembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20254699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254699.